RILUTEK IN SLOWING PROGRESSION OF FTD

RILUTEK 减缓 FTD 的进展

• 批准号: 6117185
• 负责人: Bruce Lee Miller
• 金额: $ 3.89万
• 依托单位: LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-12-01 至 1999-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6117185
• 关键词: clinical research; clinical trials; dementia; drug screening /evaluation; electromyography; human middle age (35-64); human old age (65+); human subject; human therapy evaluation; magnetic resonance imaging; mental disorder chemotherapy; neuropharmacologic agent; psychological tests; single photon emission computed tomography

To investigate the medicine Rilutek as a possible treatment for Frontotemporal Dementia. Rilutek is currently approved by the FDA for treatment of amyotrophic Lateral Sclerosis. FTD is a cortical degenerative disorder that often occurs in association with ALS. The relationship between ALS and FTD is unexplained but needs further study. Patients with FTD between the ages of 40 and 90 years of age, Patients will have their memory and thinking tested, will have an MRI, SPECT and EMG performed and will have blood drawn at every visit to monitor ...

研究药物利鲁替克作为一种可能的治疗方法 额颞部痴呆。Rilutek目前已被FDA批准用于 肌萎缩侧索硬化症的治疗。FTD是一种皮质 常与肌萎缩侧索硬化症相关的退行性疾病。这个 ALS和FTD之间的关系尚不清楚，但需要进一步研究。 年龄在40岁到90岁之间的FTD患者， 将对他们的记忆力和思维能力进行测试，并进行核磁共振、SPECT和 进行肌电检查，并将在每次探视时抽血进行监测。